Lipella pharmaceuticals successfully completes phase 2a clinical trial; announces late-breaking presentation at the annual meeting of the american urological association

Pittsburgh, march 16, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: "lipo") ("lipella," "our, "us" or the "company") today announced the successful completion of a phase 2a clinical trial evaluating the safety and efficacy of its drug candidate lp-10 for hemorrhagic cystitis.
LIPO Ratings Summary
LIPO Quant Ranking